.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The VIBRANT phase 3 randomized trial evaluated intravitreal aflibercept for macular edema following branch retinal vein occlusion (BRVO), comparing it with grid laser photocoagulation. The trial showed clinically meaningful visual benefits with aflibercept, helping establish anti-VEGF therapy as a major treatment strategy for BRVO-associated macular edema. The study is relevant to retina practice because BRVO management often requires decisions about injection frequency, rescue therapy, and expectations for visual recovery. The evidence also illustrates the evolution from laser-based treatment toward intravitreal anti-VEGF approaches. For HCPs, the practical message is to recognize the treatable nature of macular edema secondary to BRVO and to use OCT and visual acuity together when monitoring response. The timing of treatment matters, and contemporary data continue to support early control of edema rather than allowing prolonged retinal thickening and photoreceptor disruption. In real-world practice, treatment plans must also account for systemic vascular risk factors, recurrence, adherence, and the patient's ability to return for serial injections and imaging.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The VIBRANT phase 3 randomized trial evaluated intravitreal aflibercept for macular edema following branch retinal vein occlusion (BRVO), comparing it with grid laser photocoagulation. The trial showed clinically meaningful visual benefits with aflibercept, helping establish anti-VEGF therapy as a major treatment strategy for BRVO-associated macular edema. The study is relevant to retina practice because BRVO management often requires decisions about injection frequency, rescue therapy, and expectations for visual recovery. The evidence also illustrates the evolution from laser-based treatment toward intravitreal anti-VEGF approaches. For HCPs, the practical message is to recognize the treatable nature of macular edema secondary to BRVO and to use OCT and visual acuity together when monitoring response. The timing of treatment matters, and contemporary data continue to support early control of edema rather than allowing prolonged retinal thickening and photoreceptor disruption. In real-world practice, treatment plans must also account for systemic vascular risk factors, recurrence, adherence, and the patient's ability to return for serial injections and imaging.
last month
Preclinical findings demonstrate that ginsenoside Ra1 preserves vascular integrity and attenuates multi-organ injury during sepsis by targeting non-muscle myosin heavy chain IIA (NMMHC IIA) and dampening TLR4/NF-κB/NLRP3 inflammatory signaling.
2 days back
An all-printed immunosensing microchip detects urinary sFlt-1 in just 10 minutes with 3.61 pg/mL sensitivity. By leveraging photonic bandgap engineering, this low-cost, cleanroom-free platform provides non-invasive preeclampsia screening, offering substantial benefits for point-of-care obstetric triage.
3 days back
Wearable ultrasound patches are transforming healthcare by shifting medicine from episodic evaluations to continuous monitoring. Discover how flexible acoustic transducers advance cardiovascular tracking, musculoskeletal imaging, neuromodulation, and on-demand closed-loop theranostics.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
